Ausgabe Sonderheft 2/2011
IX Madrid Breast Cancer Conference
Inhalt (27 Artikel)
Poly(ADP-ribose) polymerase inhibitor development: are we in the right direction?
R Plummer
Epithelial-mesenchymal transition as a mechanism for the progression of breast carcinoma
JP Thiery, WJ Sim, K Chua, R Huang, S Mori, T Tan, FC Bidart, JY Pierga
Insulin resistance in breast cancer: relevance and clinical implications
PJ Goodwin
Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer
J Baselga, F Costa, H Gomez, C Hudis, B Rapoport, H Roche, LS Schwartzberg, O Petrenciuc, M Shan, WJ Gradishar
Clinical features and prognosis of tubular breast cancer
M Izquierdo Sanz, F Tresserra Casas, G Nacho Rodríguez, R Fabregas Xaurado, M Cusido Gimferrer, C Ara Perez, S Baulies Caballero
Abstract withdrawn
Nestin and collagen triple helix repeat containing 1 in breast cancer progression
G Kharaishvili, D Simkova, M Cizkova, K Bouchalova, G Mgebrishvili, Z Kolar, J Bouchal
Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy
L Manso, E Ciruelos, M Codes, J De la Haba, A Galan, J Baena, A Jaen, M Gil, A Murias, I Blancas, E Gonzalez, D Perez, JL Bayo, J Mel, E Garcia-Martinez, R Cubedo, J Salvador
Oestrogen receptor status predicts for local recurrence following wide local excision for breast tumours
JWK Lee, CTM Ong, EY Tan, MYP Chan
Getting deep in the luminal B breast cancer subtype and its ki67 cut-off value
E Ciruelos, C Castaneda, T Pascual, E Andrés, HL Gomez, L Manso, N Valdivieso, I Ghanem, H Cortes-Funes
Lobular carcinoma of the breast: outcome of 205 patients
E Vega, E Ciruelos, N Valdiviezo, C Mendiola, L Manso, I Ghanem, M Dorta, T Pascual, C Flores, H Cortés-Funes
BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients
K Bouchalova, M Cizkova, R Trojanec, V Koudelakova, L Radova, J Furstova, B Melichar, K Cwiertka, G Kharaishvili, Z Kolar, M Hajduch
Role of CCND1 and C-MYC oncogenes in metastatic breast cancer patients treated by herceptin
R Trojanec, V Koudelakova, K Bouchalova, L Radova, H Ondryasova, E Krejci, M Megova, M Cizkova, S Mlcochova, B Melichar, M Hajduch
microRNA and protein expression in breast cancer formalin-fixed paraffin-embedded samples
A Gámez-Pozo, I Sánchez-Navarro, CA Castaneda, NI Ferrer, G de Velasco, FG Martínez, E Ciruelos, JÁ Fresno Vara
Quantitative proteomics reveals novel proteins and central pathways associated with endocrine resistance in breast cancer
S Løkkegaard, M Bennetzen, D Elias, A Lykkesfeldt, LE Johansen, R Leth-Larsen, JS Andersen, HJ Ditzel
The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer
KH Gravgaard, MB Lyng, A-V Laenkholm, R Søkilde, BS Nielsen, T Litman, HJ Ditzel